Resource Center

More to Explore - Information About Blood Cancers for Patients, Families and Healthcare Professionals

The Word:


May 1, 2013 - Update on CLL

Your order contains  item(s)  View Order

Note: The free Adobe Acrobat Reader® is required to view and print Adobe PDF files, and the free Windows Media Player or RealPlayer is required to listen to the MP3 audio files.

Date: May 1, 2013
Time: 1:00 p.m. - 2:00 p.m. ET
Location: Telephone/Web
View: Program Slides
Read: CLL Spotlight | Transcript
Listen: Presentation | Q&A Session | Extended Q&A
Access: Virtual Lecture

Topics Covered

  • CLL signs and symptoms
  • Tests used to diagnose and stage CLL
  • Current and emerging treatments for CLL patients
  • Personalized CLL treatment plans
  • Importance of clinical trials to improve CLL patient outcomes
  • CLL side effects management and quality of life


John C. Byrd, MD
D. Warren Brown Chair of Leukemia Research
Professor of Medicine, Medicinal Chemistry, and Veterinary Biosciences
, Division of Hematology, Department of Medicine
The Ohio State University
Columbus, Ohio

Questions Asked by the CLL Community

  • Does spontaneous remission happen often?
  • Is there a treatment in pill form that will soon be approved by the FDA and will this pill keep patients in remission?
  • Are patients with CLL at higher risk of developing skin cancer than the general population?
  • What is the actual life span of a CLL patient? 
  • Will there be any clinical trials for someone older, age 78, and in stage 4 CLL?
  • Is there any news about the vaccine Genitope for CLL?
  • You said lenalidomide (Revlimid®) is approved by NCCN. Is that different than when a drug is approved by the FDA?
  • Are there any studies on milk thistle seed extract driving the white count down?
  • Please address the clinical relevance of minimal residual disease (MRD) as it applies to CLL survivors and post-chemo follow-up monitoring and/or re-intervention.
  • What is the preferred treatment for a senior who has had multiple therapies over the last four years?
  • Given that CLL affects a patient's immune system, should a patient avoid taking any medications with a warning label stating that it may affect the immune system?
  • Is a CLL patient's immune system compromised whether they are on treatment or not?
  • Does having angioneurotic edema and ulcerative colitis affect a patient's CLL in any way?
  • Does having high cholesterol have anything to do with CLL?
  • Is CLL genetic? Can it be passed on to children?
  • You talked about the drug ofatumumab. Is it the same as the drug Arzerra®?
  • Do you have any recommendations on how to handle anxiety during watch and wait? 

Sponsors and Supporters

This program is sponsored by The Leukemia & Lymphoma Society and supported by a grant from Teva Oncology.

last updated on Thursday, March 19, 2015